1899921-05-1

Basic information

• Product Name: N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide
• CAS NO: 1899921-05-1
• Molecular Weight: 525.654
• Mol File: 1899921-05-1.mol

Chemical Properties

• Density: 1.24±0.1 g/cm3(Predicted)
• CAS DataBase Reference: N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide(1899921-05-1)
• EPA Substance Registry System: N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide(1899921-05-1)

Safety Data

• Hazardous Substances Data: 1899921-05-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide is used as a potential pharmaceutical agent for targeting specific biological pathways or enzymes due to its complex structure and the presence of various functional groups that may interact with biological targets.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry research, N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide serves as a subject for studying the effects of its structural elements on biological activity, potentially leading to the discovery of new drug candidates or mechanisms of action.
Used in Chemical and Biochemical Industries:
N-(5-((4-(1-cyclopropyl-1H-benzazole-3-yl)pyrimidine-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propenamide is used in the chemical and biochemical industries for research and development, where its complex structure may offer insights into new synthetic pathways or applications in material science.

Upstream product

• 814-68-6 acryloyl chloride 
• 120-72-9 indole 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 2134096-03-8 C₃₀H₃₅N₇O₂*(x)ClH 

Relevant articles and documents

Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity

EGFR inhibitors represent a significant milestone for treatment of non-small cell lung cancer, however, they suffer from the acquired drug resistance. Utilizing osimertinib as the lead compound, this work has explored the structural modifications on the indole and pyrimidine rings of osimertinib to generate novel osimertinib derivatives. The in vitro enzymatic and cellular studies showed that the derivatives possessed high selectivity towards double mutant EGFR and potent antitumor activity. Particularly, compound 6b-1, the most active compound, exhibited excellent inhibitory activity against double mutant EGFR (IC50 = 0.18 nM) and wild-type EGFR (IC50 = 2.89 nM) as well as H1975 cells (IC50 = 1.44 nM). Western blot analysis showed that 6b-1 completely inhibited double mutant EGFR and Erk phosphorylation. In vivo test using xenograft model indicated that compound 6b-1 had better antitumor efficacy than osimertinib. More importantly, 6b-1 displayed many advantages in the pharmacokinetic study, including better oral bioavailability and metabolism character.

Preparation method of third-generation epidermal growth factor receptor (EGFR) inhibitor

The invention relates to a preparation method of a third-generation epidermal growth factor receptor (EGFR) inhibitor. The invention discloses a preparation method and application of an EGFR inhibitor. In particular, the present invention relates to a method for preparing a 4-(1-cyclopropyl-1H-indol-3-yl)-N-phenylpyrimidin-2-amine derivative with a compound structure of a formula (I). The method provided by the invention overcomes defects existing in the prior art and greatly reduces cost, and the obtained product has good purity, high yield, high process operability and greatly improved process safety. Therefore, the preparation method and application provided by the invention are suitable for industrial applications.

Preparation method of 4-(1-cyclopropyl-1H-indole-3-yl)-N-phenylpyrimidine-2-amine derivative

The invention relates to a preparation method of a 4-(1-cyclopropyl-1H-indole-3-yl)-N-phenylpyrimidine-2-amine derivative. The structural formula of the derivative is shown in the descriptions of theinvention. Specifically, the invention relates to a preparation method of a 4-(1-cyclopropyl-1H-indole-3-yl)-N-phenylpyrimidine-2-amine derivative with a compound structure as shown in a general formula (IV). According to the method, defects in the prior art are overcome, cost is greatly reduced, an obtained product is good in purity, high in yield and strong in process operability, and process safety is also greatly improved. Therefore, the preparation method and the application thereof are suitable for industrial application.

Preparation method for antagonizing drug-resistance anti-tumor EGFR (Epidermal Growth Factor Receptor) inhibitor

The invention relates to a preparation method for an antagonizing drug-resistance anti-tumor EGFR (Epidermal Growth Factor Receptor) inhibitor. Specifically, the invention relates to a preparation method for a 4-(1-cyclopropyl-1H-indole-3-yl)-N-phenylpyrimidine-2-amine derivative of a compound structure shown in a general formula (IV). According to the method, defects in the prior art are overcome; cost is greatly shortened; an obtained product has high purity, high yield and high technical maneuverability; and technical safety is greatly improved. Therefore, the preparation method disclosed by the invention and the application of the preparation method are suitable for industrial application.

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.